Truste Ppt

BUSINESS PRESENTATION FOR TRUSTE LIGHTENER

      

DERMA MARKET Aug.'05 MAT

Market Size (US $ Mn) CAGR ( %)

350 9

% Market Share in IPM

5.17

No. of active players

100

No. of active brands

1000

C-MARC & ORG IMS 



CMARC: CPR JULOCT'03

NOVFEB'04

MARJUN'04

TOP INDICATIONS OF DERMAT

100.0

100.0

100.0

DERMATITIS

9.9

10.3

9.8

CHRONIC

ACNE VULGARIS

11.0

11.0

9.4

CHRONIC

FUNGAL INFECTION

10.8

8.8

7.7

ACUTE

URTICARIA

6.1

4.9

4.6

ACUTE

MELASMA

3.4

3.5

3.6

COSMETOLOGY

PSORIASIS

3.1

3.7

3.6

CHRONIC

VITILIGO

3.5

3.1

3.5

CHRONIC

ALOPECIA

2.9

2.4

2.3

COSMETOLOGY

PHOTODERMATITIS

0.9

0.9

1.7

COSMETOLOGY

INDICATIONS Rx TOTAL

SEGMENT

Disease segmentation 2003

Disease segmentation 1999 17%

2%

3%

21%

76%

81%

RETAIL AUDIT SALE IMS Disease segmentation 2007 7% 26%

67%









    











   

    

TYROSINE (AMINO ACID) TYROSINASE DOPA (Dihydroxyphenylalanine)

CYSTEINE OR GLUTATHIONE

DOPAQUINONE

CYSTEINYL DOPA OR GLUTATHIONE DOPA

AUTO OXIDATION DOPACHROME

PHENOMELANIN YELLOW OR RED PIGMENT

DI HYDROXYINDOLE OR DI HYDROXY-2 CARCOXYLIC ACID (DHCA) EUMELANIN (BROWN BLACK PIGMENT)

DOPACHROME TAUTOMERASE AND DHCA OXIDASE

Principles of Therapy 











 Topical



Kligman formula



Chemical peeling





de pigmenting agents:

Microdermabrasion: Laser resurfacing:

ACTION

AGENTS

TYROSINASE INHIBITOR

HYDROQUINONE KOJIC ACID AZELAIC ACID LICORICE P-T ARBUTIN MELAWHITE

INHIBITION OF MELANIN PRODUCTION

ASCORBIC ACID, MAGNESIUM-L- ASCORBYL-2PHOSPHATE GLUTATHIONE

SELECTIVE MELANOCYTE TOXICITY

AMMONIATED MERCURY ISOPROPYL CATECHOL N-ACETYL-4-S— CYSTEMINYLPHENOL N-2,4-ACETOXYPHENYLTHIOETHYLACETAMIDE N- ACETYLCYSTEINE

NONSELECTIVE SUPPRESSION OF MELANOGENESIS

INDOMETHACIN CORTICOSTEROIDS

HYDROQUINONE      

HYDROQUINONE      

TRETINOIN 





KLIGMAN’S FORMULA

COMMON UNDESIRABLE EFFECTS OF KLIGMAN'S FORMULA

Facial Erythema Acneiform Eruptions Contact Dermatitis Increased Growth Of Vellus hair Leukoderma

KOJIC ACID (2-4% ) A fungal metabolic product produced by species of Aspergillus and Penicillium. Less effective than HQ, 2%. Inactivates Tyrosinase by the chelation of copper and suppresses the tautomerization from Dopachrome to 5,6-dihydroindole-2-carboxy acid A free radical scavenger. The main undesirable effect is mild facial erythema

OIL-SOLUBLE LICORICE EXTRACT The major component is Glabridin (10-40%). At the level of 50% inhibition of Tyrosinase activity, it has an efficacy 16 times greater than that of HQ. In the near future, HQ or Kojic acid will be replaced by licorice in a new and promising preparation for dermal melasma

ARBUTIN-THE SAFE HYDROQUINONE

Consists of a molecule of Hydroquinone bound to glucose . Competes with DOPA at it receptor site on Tyrosinase The percentage inhibition and efficacy are weaker than those observed for kojic acid.

Ascorbic acid 

Glutathione 

.

REMOVAL OF MELANIN 

  

COMBINATION THERAPIES Synergic effect Shortens the duration of therapy Reduces the risk of adverse effect



 

 

MAT DEC 2004

 

 

 

MAT DEC 2005

 

 

 

 

UNITS

RUPEE

M.S.

 

UNITS

RUPEE

M.S

GROWT H

DEMELANIZING AGENTS MELALITE CLEARZ

NPL DRL

3,755,612

127,778,559

100%

 

4,632,186

191,694,382

100%

50%

842,204

31,110,372

24%

 

771,986

30,517,393

16%

-2%

348,178

26,075,055

20%

 

356,192

27,699,375

14%

6%

32,133

2,395,318

2%

 

303,998

23,743,347

12%

891%

MELACARE

AJA

MELALITE-15

NPL

344,362

13,283,298

10%

 

546,252

22,361,167

12%

68%

EUKROMA

YSP

830,907

17,626,657

14%

 

870,425

19,681,737

10%

12%

422,706

8,695,131

7%

 

470,585

10,409,506

5%

20%

0

0

0%

 

83,341

9,904,249

5%

402,109

8,416,142

7%

 

264,954

7,314,984

4%

0

0

0%

 

113,778

5,987,100

3%

BRITE DEMELAN ESLITE HYCLEAN

WL/ GMK ELD RBY

  -13%  

: Rx RESPONSE TREND

Sps. DERMAT

BASE :JAN. - DEC.2002 : FOUR MONTHLY AVG.:100

200 180 MELANIZING+DEME LANI+PEELING AG

160 140

DEMELANIZING AGENTS (DER)

120

MELANIZING AGENTS (DER)

100 80 60 40 20

N-F'06

J-O'05

M-J'05

N-F'05

J-O'04

M-J'04

N-F'04

J-O'03

BASE

0

MELANIZING+DEMELANI+PEELING AG

Sps: DERMAT

Absolute :Rx Response Trend (Four Monthly)

MOLECULE \ BRAND

JULY'03- NOV'03- MAR'04- JUL'04OCT'03 FEB'04 JUNE'04 OCT'04 536

DEMELANIZING AGENTS (DER)

522

719

670

MELACARE CREAM [AJNTA-ZILION] 15

CLEARZ CREAM [DRL - RECURA]

203

170

NOV'04- MAR'05- JULY'05- NOV'05FEB'05 JUNE'05 OCT'05 FEB'06 816

896

892

980

4

132

167

186

237

174

145

144

50

97

120

1

107

83

62

47

53

HYCLEAN CREAM [RBXY-CRL DER] DEMELAN CREAM [GLEN-GRACWEL] EUKROMA CREAM [YASH Pharma ] 76 KOJIC CREAM [CURATIO

83

62

68

62

12

]

BAN A TAN CREAM [CURATIO

11

]

808

690

769

693

678

707

679

644

PLACENTREX GEL [ALBERT DAVID]142

105

124

96

99

99

86

79

MELANIZING AGENTS (DER)

MELANOCYL TAB [FRANCO (I) ]

95

84

95

98

96

86

76

70

OCTAMOP TAB [PALSONS

94

69

75

71

70

83

62

61

59

41

55

55

66

55

73

49

70

73

69

54

50

62

46

]

VITILO LOTION [ELD-ELDERMIS]

68 PLACENTREX LOTION [ALBERT DAVID]

         

   

Drs currently need:

CURATIO’S PRESENCE IN MELASMA MARKET

LICORICE ARBUTIN COSMOPERINE

KOJIC ACID 2%

RETAIL SALES 14000 12000 10000 BANATAN

8000

KOJIC 6000

TOTAL

4000 2000 0 Oct- Nov- Dec- Jan05 05 05 06

Feb- Mar- Apr- May- Jun- Jul-06 Aug06 06 06 06 06 06

CURATIO GAINING Rx IN C-MARC DATA   RANK

 

MAR-APR 06

JAN-FEB 06

MAR-APR 05

PREV

CORR

1462

1479

1353

-17

109

134

116

72

18

62

1

MELACARE

2

MELALITE

80

81

72

-1

8

3

HYCLEAN

64

74

11

-10

53

4

CLEARZ

61

103

103

-42

-42

5

CLEARZ PLUS

50

30

6

EUKROMA

43

34

7

DEMELAN

37

59

8

MELALITE FORTE

32

31

49

1

-17

9

ESLITE

32

29

61

3

-29

10

BRITE

30

32

34

-2

-4

11

VANISH

27

25

27

2

0

12

BAN A TAN

27

10

13

EUKROMA SG

25

28

26

-3

-1

14

GLYAHA HQ

23

21

37

2

-14

15

KOJIC

23

10

 

13

 

16

EUKROMA PLUS

20

11

 

9

 

17

HYDE

18

24

 

20 50

 

9 -22

 

17

28

 

-6

-7  

 

-10

TRUSTE LIGHTENING ESSENCE Aqua, Cetearyl Ethylhexanoate, Cetearyl Alcohol, Butylene Glycol, Tocopheryl Acetate, Glycolic Acid, Kojic Dipalmitate. Arbutin, Lactic Acid, Sodium Lauryl Sulphate, Ascorbic Acid, Dimethicone, Sodium Sukphite, Arginine, Disodium EDTA, Phenoxyethanol, Solanum Lycopersicum (Tomato) Extract : Solano Complex

SWOT Strengths:

Opportunities:

Customer knowledge of the team Differentiated products Presence in Melasma Customer reach Credibility built in short time

High incidence of Melasma End consumer awareness gap. Growing affluence of customers Growing business potential per DR. Need for Niche and effective products.

Weaknesses: High investment required for CRM Initiatives.

Threats: Emergence of cosmetology players Entry of Global giants like “VICHY” Price barriers Players with Derma specific field force coming in Entrance of high end beauty parlors & Cosmetic clinics